Molecular Biology RNA Small Molecule 
Drug Discovery World
APRIL 11, 2023
US-based start-up Atomic AI is using artificial intelligence (AI) to design more intelligent RNA-targeted and RNA-based medicines. As tech experts call for improved regulation and a halt to the development of AI, we take a look at how one company, Atomic AI, is using it to develop RNA-targeting treatments for a range of diseases.
Drug Discovery World
FEBRUARY 27, 2023
DDW’s Diana Spencer speaks to Raphael Townshend PhD, Founder and CEO of Atomic AI, about the company’s successes so far, plans for the future and the unique approach of combining RNA structural biology and AI models. DS: How is Atomic AI “unlocking the next generation of RNA drug discovery”? What is unique about your engine?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 26, 2023
Atomic AI, a biotechnology company fusing machine learning with structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round. Atomic AI is oriented at the cutting edge of AI, RNA, and structural biology.
DrugBank
MAY 15, 2024
But as molecular biology has advanced, so too has our approach to finding new drugs. Today, we're able to identify and target specific molecules involved in disease processes—a method that's much more like using a sniper rifle than throwing darts blindfolded. This method was more about serendipity than science.
Drug Discovery World
DECEMBER 26, 2023
Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe. His research focuses on immunotherapies for patients with breast cancer.
Drug Target Review
DECEMBER 7, 2023
Phage have been of interest to scientists as tools to understand fundamental molecular biology, as vectors of horizontal gene transfer and drivers of bacterial evolution, as sources of diagnostic and genetic tools, and as novel therapeutic agents. He continued: “CBASS cyclases look a lot like cGAS, so they have to be sensing something.
Dark Matter Blog
JULY 16, 2021
The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA.
Expert insights. Personalized for you.
130 
Let's personalize your content